Randomized data from CMB305 + checkpoint inhibitor study show clinical benefit and immune response October 03, 2017Vol.40 No.08
Safety review update of Revlimid and risk of developing new types of malignancies October 03, 2017Vol.40 No.08
Two Opdivo trials show three-year survival in patients with previously treated advanced NSCLC October 03, 2017Vol.40 No.08
Drugs & Targets FDA approves treatment to reduce risk of breast cancer returning August 03, 2017Vol.40 No.07
Experimental “enhancer” may boost conventional therapies for pediatric disease August 03, 2017Vol.40 No.07
Combined molecular biology test can identify patients with benign pancreatic abnormalities August 03, 2017Vol.40 No.07
Differences in subtypes may determine prognosis and response to treatment August 03, 2017Vol.40 No.07
